IDEXX Laboratories Announces Second Quarter Results
? Reports revenue growth of 14% on a reported basis and 12% on an organic basis, driven by CAG
Diagnostics recurring revenue growth of 15% reported and 13% organic
? Achieves 3,241 premium instrument placements, representing 21% year-over-year growth
? Delivers EPS of $1.23, a 29% increase year-over-year on a reported basis or 33% on a comparable
constant currency basis
? Adjusts 2018 revenue guidance to $2,205 million – $2,230 million, reflecting reported growth of
12% - 13.5%; increases organic revenue growth outlook to 11.5% - 12.5%; offset by impacts related
to strengthening of the U.S. dollar
? Increases 2018 EPS outlook range to $4.10 - $4.20, $0.02 above the midpoint of prior guidance, as
benefits from operating performance and from a lower projected effective tax rate are partially
offset by negative impact of updated foreign exchange assumptions
https://idexxcom-live-b02da1e51e754c9cb292133b-9c56c33.aldryn-media.com/filer_public/6b/bb/6bbb2ed9-6faf-47c3-9a08-4d65ddf78596/2018-q2-earnings-release-20180801.pdf
